Realistic biological approaches for improving thermoradiotherapy

References

• Overgaard J. Rationale and problems in the design of clinical trials. In: Overgaard J, editor. Hyperthermic Oncology, Vol. 2. London: Taylor and Francis; 1985. pp 325–38
   Google Scholar
• Horsman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clin Oncol 2007;19:418–26
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487–97
   PubMed Web of Science ®Google Scholar
• Franckena M. Review of radiotherapy and hyperthermia in primary cervical cancer. Int J Hyperthermia 2012;28:543–8
   PubMed Web of Science ®Google Scholar
• Datta NR, Ordonez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, et al. Local hyperthermia combined with radiotherapy and/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev 2015. PMID: 26051911
   Google Scholar
• Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807–12
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(Suppl16):15–18
   PubMed Web of Science ®Google Scholar
• Hahnfeldt P, Panigrahi D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: A dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770–5
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401–10
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: A review. Cancer Res 1989;49:6449–65
   PubMed Web of Science ®Google Scholar
• Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Sem Radiat Oncol 2004;14:198–206
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–87
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther 2015;153:107–24
   PubMed Web of Science ®Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977;123:511–14
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979;39:966–72
   PubMed Web of Science ®Google Scholar
• Jain RK, Grantham FH, Gullino PM. Blood flow and heat transfer in Walker 256 mammary carcinoma. J Natl Cancer Inst 1979;62:927–33
   PubMed Web of Science ®Google Scholar
• Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 1979;5:235–41
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Honess DJ, Morgan JE. Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer 1977;35:299–306
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J, Chaplin DJ. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay. Acta Oncol 1988;27:861–62
   PubMed Web of Science ®Google Scholar
• Mao HS, Grau C, Overgaard J. Interaction of misonidazole, hyperthermia, and irradiation in a C3H mammary carcinoma and its surrounding skin in vivo. Int J Radiat Oncol Biol Phys 1992;22:115–22
   PubMed Web of Science ®Google Scholar
• Masunaga S-I, Liu Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N, et al. Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential. Int J Hyperthermia 2012;28:636–44
   PubMed Web of Science ®Google Scholar
• Borad MJ, Reddy SG, Bahary N, Uronis HE Sigal D, Cohn AL, et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2015;33:1475–81
   PubMed Web of Science ®Google Scholar
• Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, et al. TH-30, a hypoxic-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012;69:1487–98
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SH, Alfieri AA, Young CW. Quercetin, an inhibitor of lactate transport and a hyperthermic sensitizer of HeLa cells. Cancer Res 1984;44:102–6
   PubMed Web of Science ®Google Scholar
• Asea A, Ara G, Teicher BA, Stevenson MA, Calderwood SK. Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 2001;17:347–56
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SH, Alfieri A, Young CW, Silvestrini B. Lonidamine: A hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo. Oncology 1984;41(Suppl):30–5
   PubMed Web of Science ®Google Scholar
• Coss RA, Storck CW, Wells TC, Kulp KA, Wahl M, Leeper DB. Thermal sensitization by lonidamine of human melanoma cells grown at low extracellular pH. Int J Hyperthermia 2014;30:75–8
   PubMed Web of Science ®Google Scholar
• Hiraoka M, Hahn GM. Changes in pH and blood flow induced by glucose, and their effects on hyperthermia with or without BCNU in RIF-1 tumours. Int J Hyperthermia 1990;6:97–103
   PubMed Web of Science ®Google Scholar
• Urano M. Tumor response to hyperthermia. In: Urano M, Douple EB, editors. Hyperthermia and Oncology, Vol. 1. Utrecht: VSP; 1988. pp 161–200
   Google Scholar
• Burd R, Lavorgna SN, Daskalakis C, Wachsberger PR, Wahl ML, Biaglow JE, et al. Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine. Radiat Res 2003;159:328–35
   PubMed Web of Science ®Google Scholar
• Kalliomaki T, Hill RP. Effects of tumour acidification with glucose + MIBG on the spontaneous metastatic potential of two murine cell lines. Br J Cancer 2004;90:1842–9
   PubMed Web of Science ®Google Scholar
• Stryker JA, Gerweck LE. Lonidamine-induced, pH dependent inhibition of cellular oxygen utilization. Radiat Res 1988;113:356–61
   PubMed Web of Science ®Google Scholar
• Lee I, Glickson JD, Dewhirst MW, Leeper DB, Burd R, Poptani H, et al. Effect of mild hyperglycemia ± meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. Adv Exp Med Biol 2003;530:177–86
   PubMed Web of Science ®Google Scholar
• Kim JH, Alfieri AA, Kim SH, Young CW. Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 1988;46:1120–3
   Web of Science ®Google Scholar
• Kim JH, Kim SH, He SQ, Alfieri AA, Young CW. Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine. Int J Radiat Oncol Biol Phys 1989;16:1277–80
   PubMed Web of Science ®Google Scholar
• Wouters BG, Begg AC. Irradiation-induced damage and the DNA damage response. In: van der Kogel AJ, Joiner M, editors. Basic Clinical Radiobiology for Radiation Oncologists, 4th ed. London: Hodder Arnold; 2009. pp 233–45
   Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 2001;77:399–408
   PubMed Web of Science ®Google Scholar
• Ihara M, Takeshita S, Okaichi K, Okumura Y, Ohnishi T. Heat exposure enhances radiosensitivity by depressing DNA-PK kinase activity during double strand break repair. Int J Hyperthermia 2014;30:102–9
   PubMed Web of Science ®Google Scholar
• Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia 2012;28:509–17
   PubMed Web of Science ®Google Scholar
• Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Oncol Targets Therapy 2015;8:519–28
   PubMed Web of Science ®Google Scholar
• O’Connor MJ, Martin NMB, Smith GCM. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816–24
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. PNAS 2011;108:9851–6
   PubMed Web of Science ®Google Scholar
• Thiesen B, Jordan A. Clinical implications of magnetic nanoparticles for hyperthermia. Int J Hyperthermia 2008;24:467–74
   PubMed Web of Science ®Google Scholar
• Hilger I. In vivo applications of magnetic nanoparticle hyperthermia. Int J Hyperthermia 2013;29:828–34
   PubMed Web of Science ®Google Scholar
• Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352–6
   PubMed Web of Science ®Google Scholar
• Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yaun F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335–44
   PubMed Web of Science ®Google Scholar
• Yardley DA, Burrias HA III, Spigel DR, Clark BL, Vazquez E, Shipley D, et al. A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clin Breast Cancer 2009;9:247–52
   PubMed Web of Science ®Google Scholar
• Richards DA, Loesch D, Vukelja SV, Wu H, Hyman WJ, Nieves J, et al. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Invest New Drugs 2011;29:963–70
   PubMed Web of Science ®Google Scholar
• Landen CD, Park J-Y, Needham D, Dewhirst DW. Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed 2011;3:38–64
   PubMedGoogle Scholar
• McDaniel JR, Dewhirst MW, Chilkoti A. Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia. Int J Hyperthermia 2013;29:501–10
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, Park J-Y, Simnick AJ, Needham D, et al. Overcoming limitations in nanoparticle drug delivery: Triggered intravascular release to improve drug penetration into tumors. Cancer Res 2012;72:5566–75
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010;26:514–21
   PubMed Web of Science ®Google Scholar
• Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O’Connor B, et al. Two phase I dose-escalation/pharmacokinetic studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia 2014;30:285–94
   PubMed Web of Science ®Google Scholar
• Davies CDL, Lundstrøm LM, Frengen J, Eikenes L, Bruland ØS, Kaalhus O, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Cancer Res 2004;64:547–53
   PubMed Web of Science ®Google Scholar
• Petznek H, Kleityer M, Tichy A, Fuchs-Baumgartinger A, Hohenadl C. Murine xenograft model demonstrates significant radio-sensitising effect of liposomal doxorubicin in a combination therapy for feline injection site sarcoma. Res Vet Sci 2014;97:386–90
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000;39:207–11
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G., Koukouraki GV, Retalis G, et al. Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: Excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 2002;87:385–92
   PubMed Web of Science ®Google Scholar
• Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res 2013;1:210–16
   PubMed Web of Science ®Google Scholar
• Repasky EA. Progress in development of biomedical applications of heat shock proteins and thermal stress. Int J Hyperthermia 2013;29:359–61
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia 2014;30:531–9
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718–26
   PubMed Web of Science ®Google Scholar
• Gaipl US, Multhoff G, Scheithauer H, Lauber K, Hehlgans S, Frey B, et al. Kill and spread the word: Simulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 2014;6:597–610
   PubMed Web of Science ®Google Scholar
• Vartak S, George KC, Singh BB. Antitumor effects of local hyperthermia on a mouse fibrosarcoma. Anticancer Res 1993;13:727–29
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Shi Y, Javidiparsijani S, Wang G, Li X, et al. Abscopal antitumor immune effects of magnet-mediated hyperthermia at a high therapeutic temperature on Walker-256 carcinosarcomas in rats. Oncol Lett 2014;7:764–70
   PubMed Web of Science ®Google Scholar
• Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Frontiers Oncol 2014;4:325
   PubMedGoogle Scholar
• Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015;41:503–10
   PubMed Web of Science ®Google Scholar
• Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, et al. Combining radiation and immunotherapy: A new systemic therapy for solid tumors? Cancer Immunol Res 2014;2:831–8
   PubMed Web of Science ®Google Scholar
• Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: Potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 2014;182:126–38
   PubMed Web of Science ®Google Scholar
• Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008;44:2546–54
   PubMed Web of Science ®Google Scholar
• Kabakov AE, Kudryavtsev VA, Gabai VL. Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 2010;80:241–7
   Web of Science ®Google Scholar
• Hall JA, Forsberg LK, Blagg BSJ. Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med Chem 2014;6:1587–605
   PubMed Web of Science ®Google Scholar
• Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. J Med Chem 2014;57:8718–28
   PubMed Web of Science ®Google Scholar
• McConnell JR, Buckton LK, McAlpine SR. Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach. Biorg Med Chem Letts 2015;25:3409–14
   PubMed Web of Science ®Google Scholar
• Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR. Phase II of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: A Mayo Clinic phase II consortium study. Invest New Drugs 2015;33:963–8
   PubMed Web of Science ®Google Scholar
• Camphausen K, Tofilon PJ. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res 2007;13:4326–30
   PubMed Web of Science ®Google Scholar
• Yoshida S, Koga F, Tatokoro M, Kawakami S, Fuji Y, Kumagai J, et al. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemotherapy. Cell Cycle 2011;10:4291–9
   PubMed Web of Science ®Google Scholar
• Patel K, Wen J, Magliocca K, Muller S, Liu Y, Chen ZG, et al. Heat shock protein (Hsp90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother Pharmacol 2014;74:1015–22
   PubMed Web of Science ®Google Scholar
• Wolf F, Li W, Li F, Li CY. Non-invasive, quantitative monitoring of hyperthermia-induced EGFR activation in xenograft tumours. Int J Hyperthermia 2011;27:427–34
   PubMed Web of Science ®Google Scholar
• Milanovic D, Firat E, Grosu AL, Niedermann G. Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol 2013;8:42
   PubMed Web of Science ®Google Scholar
• Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006;66:9211–20
   PubMed Web of Science ®Google Scholar
• Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, et al. Hsp90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008;7:1985–92
   PubMed Web of Science ®Google Scholar
• Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, et al. The Hsp90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 2012;7:e35436
   PubMed Web of Science ®Google Scholar
• Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly (ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009;8:2243–54
   PubMed Web of Science ®Google Scholar
• Horsman MR. Modifiers of tumor blood supply. In: Urano M, Douple EB, eds. Hyperthermia and Oncology, Vol. 4. Utrecht: VSP, 1994, pp. 259–83
   Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006;22:197–203
   PubMed Web of Science ®Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989;5:123–36
   PubMed Web of Science ®Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Relationship between the hydralazine-induced changes in murine tumour blood supply and mouse blood pressure. Int J Radiat Oncol Biol Phys 1992;22:455–8
   PubMed Web of Science ®Google Scholar
• Clinical trials information for patients and caregivers. US National Cancer Institute. Available from http://www.cancer.gov/clinicaltrials
   Google Scholar
• Clémenson C, Chargari C, Deutsch D. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol/Hematol 2013;86:143–60
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987–9
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520–39
   PubMed Web of Science ®Google Scholar
• Siemann DW, Dai Y, Horsman MR. Hypoxia, metastasis, and antiangiogenic therapies. In: Mellilo G, editor. Hypoxia and Cancer: Biological Implications and Therapeutic Opportunities. New York: Springer; 2014. pp 205–27
   Google Scholar
• Yano T, Tanase M, Watanabe A, Sawada H, Yamada Y, Shino Y, et al. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res 1995;14:1355–8
   Google Scholar
• Nishimura, Y., Murata, R., Hiraoka, M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996;73:270–4
   PubMed Web of Science ®Google Scholar
• Verhulst J. Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia 2013;29:62–70
   PubMed Web of Science ®Google Scholar
• Nie W, Ma XL, Sang YX, Li YL, Gao X, Xu GC, et al. Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26. Clin Exp Med 2014;14:203–13
   PubMed Web of Science ®Google Scholar
• Eikesdal, H.P., Bjorkhaug, S.T., Dahl, O. Hyperthermia exhibits anti-vascular activity in the BT4An rat glioma: Lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia 2002;18:141–52
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996;12:779–89
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195–204
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stødkilde-Jørgensen H, Overgaard J. Combretastatins: Novel vascular targeting drugs for improving anti-cancer therapy. Adv Exp Med Biol 2000;476:311–23
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047–55
   PubMed Web of Science ®Google Scholar
• Iversen AB, Busk M, Horsman MR. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Acta Oncol 2013;52:1320–6
   PubMed Web of Science ®Google Scholar
• Breidahl T, Nielsen FU, Stødkilde-Jørgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncol 2006;45:306–16
   PubMed Web of Science ®Google Scholar
• Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In: Sugahara T, Saito M, editors. Hyperthermic Oncology, Vol. 1. London: Taylor and Francis; 1989. pp 258–9
   Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996;12:335–44
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000;2:555–60
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003;19:575–89
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal and radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518–23
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting therapies and hyperthermia. In: Siemann DW, editor. Vascular-targeted Therapies in Oncology. Chichester: Wiley; 2006. pp 137–57
   Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Vascular targeting agents: Adjuvants to radiation therapy. Radiother Oncol 2000;57:5–12
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335:241–8
   PubMed Web of Science ®Google Scholar
• Folkes LK, Christlieb M, Madej E, Stratford MRL, Wardman P. Oxidative metabolism of combretastatin A-1 produces quinine intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007;20:1885–94
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001;40:497–503
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004;20:393–404
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1018–24
   PubMed Web of Science ®Google Scholar
• Hokland S, Horsman MR. The new vascular disrupting agent combretastatin A-1 disodium phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitisation. Int J Hyperthermia 2007;23:599–606
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Williams BW, Koonce NA, Bischof JC, Song CW, Asur R, et al. Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors. J Oncol 2012;2012:934918
   PubMedGoogle Scholar
• Horsman MR. The therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation. Int J Hyperthermia 2015;31:453–9
   PubMed Web of Science ®Google Scholar
• Horsman MR, Wood PJ, Chaplin DJ, Brown JM, Overgaard J. The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol 1990;18:49–57
   PubMed Web of Science ®Google Scholar
• Horsman MR, Nordsmark M, Khalil AA, Hill SA, Chaplin DJ, Siemann DW, Overgaard J. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994;33:371–6
   PubMed Web of Science ®Google Scholar
• Horsman MR, Brown DM, Lemmon MJ, Brown JM, Lee WW. Preferential tumour radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys 1986;12:1307–10
   PubMed Web of Science ®Google Scholar
• Horsman MR, Chaplin DJ, Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells. Cancer Res 1990;50:7430–6
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Horsman MR, Siemann DW. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: Importance of nicotinamide dose and pre-irradiation breathing time. Br J Cancer 1993;68:269–73
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912–18
   PubMed Web of Science ®Google Scholar
• Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 2012;30:1777–83
   PubMed Web of Science ®Google Scholar
• Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: Recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76:S87–91
   PubMed Web of Science ®Google Scholar
• Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, et al. Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys 2004;60:237–48
   PubMed Web of Science ®Google Scholar
• Moon EJ, Sonveaux P, Porporato PE, Danhier P, Gallez B, Batinic-Haberle I, et al. NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. PNAS 2010;107:20477–82
   PubMed Web of Science ®Google Scholar
• Chi J-T, Thrall DE, Jiang C, Snyder S, Fels D, Landon C, et al. Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics. Clin Cancer Res 2011;17:2549–60
   PubMed Web of Science ®Google Scholar